Aflac Incorporated

(New York Stock Exchange)
Back to all articles
Neutral 0

Quick Look at AFLAC (AFL)

AI-generated analysis

πŸ“ˆ AFLAC stock has gained 11.7% over the last year, significantly underperforming the S&P 500 which rose 27.2%.

πŸ’° The current share price is $112.64, with an average analyst target price of $112.07 and a "Hold" rating.

πŸ“Š AFLAC trades at a trailing P/E ratio of 12.9 compared to the S&P 500 average of 29.3.

πŸ“‰ The company's Price to Book (P/B) ratio is 1.92, well below the S&P 500 average of 4.74.

🏒 AFLAC operates in the Finance sector with a sector-average P/E of 15.92 and P/B of 1.78.

πŸ’΅ Trailing earnings per share (EPS) are reported at $8.75, while forward EPS is projected at $7.60.

πŸ“‰ The forward P/E ratio stands at 14.8, indicating expected earnings growth relative to current valuation.

πŸ“ˆ Reported year-over-year quarterly earnings growth shows a massive 3860.0% increase.

πŸ’Έ Gross profit margins are reported at 0.5%.

πŸ’° Free cash flow for the last quarter is $4.92 Billion.

πŸ₯ The company provides supplemental health and life insurance through two main segments: Aflac Japan and Aflac U.S.

πŸ‡―πŸ‡΅ In Japan, products include cancer, medical, nursing care, whole life, and specific endowment plans.

πŸ‡ΊπŸ‡Έ In the U.S., offerings cover accident, disability, critical illness, dental, vision, and various supplemental insurance types.

🀝 Products are sold to individuals and businesses via individual agents, corporate agencies, banks, and brokers.

πŸ“… AFLAC was founded in 1955 and is headquartered in Columbus, Georgia.

⚠️ The analysis is for educational purposes only and does not constitute a recommendation to buy or sell the stock.

πŸ“‰ Past performance and accounting data are noted as unreliable indicators of future price movements.

🧠 Investors are advised to conduct their own review and analysis before making investment decisions.

Bullish Signals
  • AFLAC has reported year-over-year quarterly earnings growth of 3860.0%, indicating a significant positive shift in profitability.
  • The company generated $4.92 Billion in free cash flow over the last quarter, demonstrating strong liquidity and operational efficiency.
  • AFLAC trades at a trailing P/E ratio of 12.9 and a forward P/E of 14.8, which are significantly lower than the S&P 500 average of 29.3, suggesting potential value.
  • The company's Price to Book ratio of 1.92 is below the S&P 500 average of 4.74 and aligns closely with the Finance sector average of 1.78, indicating a reasonable valuation relative to peers.
Risk Factors
  • AFLAC has significantly underperformed the broader market, rising only 11.7% over the last year compared to the S&P 500's gain of 27.2%.
  • Analysts maintain a 'hold' rating with a mean target price of $112.07, which is below the current trading price of $112.64, suggesting limited upside potential.
  • The company trades at a trailing P/E ratio of 12.9 and forward P/E of 14.8, both substantially lower than the S&P 500 average of 29.3 and the Finance sector average of 15.92, indicating market skepticism about future earnings growth.
  • AFLAC's Price to Book ratio of 1.92 is less than half the S&P 500 average of 4.74 and below the Finance sector average of 1.78, reflecting a low valuation relative to assets.
  • The reported year-over-year quarterly earnings growth of 3860.0% appears anomalous or non-recurring given the extremely low gross profit margin of just 0.5%, raising concerns about the quality and sustainability of earnings.
  • Despite high free cash flow, the combination of low valuation multiples and weak relative performance suggests the stock may be priced for stagnation rather than growth.
Full Analysis
AFLAC stock has gained 11.7% over the last year, significantly underperforming the S&P 500 which rose 27.2%. Analysts currently hold a neutral rating on the diversified insurance company, with a mean target price of $112.07 per share, placing the current stock price just 0.5% away from that consensus valuation. The company trades at a trailing P/E ratio of 12.9 and a forward P/E of 14.8, both substantially lower than the S&P 500 averages of 29.3 and implied future growth expectations respectively. Valuation metrics also show AFLAC trading at a Price to Book ratio of 1.92 compared to the broader market average of 4.74, while its sector peers in Finance average a P/E of 15.92 and a P/B of 1.78. Financial performance highlights include reported year-over-year quarterly earnings growth of 3860.0% and gross profit margins of 0.5%, alongside a free cash flow generation of $4.92 billion over the last quarter. The company operates through two primary segments: Aflac Japan, which offers cancer, medical, nursing care, whole life, and other specialized insurance products, and Aflac U.S., which provides accident, disability, critical illness, dental, vision, and life insurance to individuals, families, and business owners. Distribution channels include individual agents, corporate agencies, banks, and brokers across both domestic markets. Founded in 1955 and headquartered in Columbus, Georgia, the firm continues to expand its product suite to include hearing, pet, Medicare supplement, and absence management insurance options.